What is Brief History of Apellis Pharmaceuticals Company?

Apellis Pharmaceuticals Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

What is the history of Apellis Pharmaceuticals?

Apellis Pharmaceuticals is a global biopharmaceutical company focused on complement-driven diseases. They recently received FDA approval for EMPAVELI in July 2025, marking a significant milestone.

Founded in 2009, Apellis aimed to develop novel therapies by targeting the complement system. Their journey has led to significant advancements in treating rare and severe conditions.

Apellis Pharmaceuticals, established in 2009, has rapidly emerged as a leader in complement medicine. The company's dedication to addressing diseases driven by the complement system has resulted in groundbreaking therapies. A key achievement was the July 28, 2025, FDA approval of EMPAVELI for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged 12 and older. This marks a significant step in their mission to provide transformative treatments for rare and debilitating conditions. The company's commitment to innovation is further evidenced by its strong financial performance, with full-year 2024 revenues reaching $781.4 million, a 97% increase year-over-year. This growth highlights the market's positive reception to their novel approach. For a deeper dive into the external factors influencing the company's operations, consider an Apellis Pharmaceuticals PESTEL Analysis.

Apellis Pharmaceuticals was established in 2009 by Dr. Cedric Francois and Dr. Pascal Deschatelets, marking the beginning of a focused effort to address diseases linked to the complement system. Their combined scientific acumen and entrepreneurial spirit set the stage for a company dedicated to innovative therapeutic approaches.

The Genesis of Apellis Pharmaceuticals

Apellis Pharmaceuticals history began in 2009 with the vision of its founders, Dr. Cedric Francois and Dr. Pascal Deschatelets. They aimed to tackle diseases driven by the dysregulation of the complement system, a critical part of the immune response.

• Founded in 2009 by Cedric Francois, M.D., Ph.D., and Pascal Deschatelets, Ph.D.
• Dr. Francois, also a co-founder of Potentia Pharmaceuticals, leads as CEO and President.
• Dr. Deschatelets serves as the Chief Scientific Officer, bringing deep scientific expertise.
• The company's initial focus was on modulating the complement system for various severe conditions.
• Early funding of $32.5 million was secured in a Series A financing round.
• Investors included Vatera Healthcare Partners and Morningside Capital.
• The name 'Apellis' is derived from the Greek word for 'unblemished,' reflecting the goal of restoring health.
• The early years involved navigating complex drug discovery and development processes.
• The company's Revenue Streams & Business Model of Apellis Pharmaceuticals was built around this scientific foundation.

Apellis Pharmaceuticals SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Apellis Pharmaceuticals embarked on a rapid expansion following its founding, establishing a key research and development center in Waltham, Massachusetts, in 2010. This strategic move placed the company within a vibrant biotechnology hub, facilitating the advancement of its complement-targeting therapies. The company's journey from startup to public company saw significant financial milestones, underscoring its commitment to innovation in rare disease treatment.

Early Operational Expansion

In 2010, Apellis Pharmaceuticals established its research and development hub in Waltham, Massachusetts. This move was a strategic decision to integrate into a prominent biotechnology cluster, enhancing its capacity for developing its complement-targeting pipeline.

Initial Public Offering (IPO) and Funding

A significant event in the Apellis company timeline was its Initial Public Offering (IPO) in 2015, which successfully raised $150 million. This capital infusion was crucial for accelerating its clinical development programs and further solidifying its position in the market.

Strategic Acquisition and Pipeline Growth

Apellis Pharmaceuticals history includes a strategic acquisition of Potentia Pharmaceuticals on November 20, 2014. This acquisition likely strengthened its intellectual property portfolio and expanded its drug development pipeline, a key aspect of Apellis's early years and growth.

Continued Financial Growth and Leadership

Further demonstrating its financial trajectory, Apellis secured a post-IPO funding round of $329 million on May 7, 2020. The consistent leadership of its co-founders has been pivotal in guiding the company's development, as detailed in this Brief History of Apellis Pharmaceuticals.

Apellis Pharmaceuticals PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Apellis Pharmaceuticals has achieved groundbreaking milestones and innovations, fundamentally transforming the treatment landscape for complement-driven diseases, yet has also faced significant challenges. A major achievement was the FDA approval of Empaveli (pegcetacoplan) in May 2021 for paroxysmal nocturnal hemoglobinuria (PNH), marking the company's first FDA-approved product and introducing a novel C3-targeting therapy. This was followed by another landmark approval in February 2023, when SYFOVRE (pegcetacoplan injection) became the first and only FDA-approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a leading cause of blindness affecting over one million people in the U.S. and five million worldwide. More recently, on July 28, 2025, EMPAVELI received its second FDA approval, becoming the first treatment for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged 12 and older, demonstrating a 68% reduction in proteinuria and stabilization of kidney function in the VALIANT study.

Apellis Pharmaceuticals has pioneered novel therapeutic approaches by targeting the complement system, specifically C3, to address rare and underserved diseases. Their innovation lies in developing pegcetacoplan, a targeted therapy that offers a new mechanism of action for conditions previously lacking effective treatments.

C3-Targeting Therapy

Apellis developed pegcetacoplan, a first-in-class therapy targeting complement component 3 (C3). This innovative approach aims to control complement cascade activation at a central point, offering a new treatment paradigm for complement-driven diseases.

First-in-Class Treatment for GA

The approval of SYFOVRE marked a significant advancement as the first and only FDA-approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This addresses a critical unmet need for patients experiencing vision loss from this condition.

Expansion into Renal Diseases

The recent approval of EMPAVELI for C3G and IC-MPGN demonstrates the company's commitment to expanding its therapeutic reach into other complement-mediated renal diseases. This highlights the versatility of their C3-targeting platform.

Despite these successes, Apellis has encountered challenges. In Q1 2025, the company reported a net loss of $92.2 million, an increase from $66.4 million in Q1 2024, and faced headwinds with SYFOVRE sales, which fell to $130.2 million due to underfunded third-party copay assistance programs and inventory drawdowns, resulting in approximately $10 million in lost revenue.

Financial Performance

The company reported a net loss of $92.2 million in Q1 2025, an increase from the previous year, indicating ongoing investment in research and development and commercialization efforts. Full-year 2024 revenues reached $781.4 million, a 97% year-over-year increase, but the company still incurred a full-year net loss of $197.9 million.

Sales Headwinds

SYFOVRE sales in Q1 2025 experienced a decline to $130.2 million due to issues with copay assistance programs and inventory adjustments, leading to an estimated $10 million in lost revenue. This highlights the complexities of market access and reimbursement for new therapies.

Strategic Financial Adjustments

To strengthen its financial position, Apellis secured up to $300 million from a royalty purchase agreement in July 2025. This move underscores the company's proactive approach to managing financial resources amidst the inherent volatility of the biopharmaceutical sector, aligning with their Mission, Vision & Core Values of Apellis Pharmaceuticals.

Apellis Pharmaceuticals Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Apellis Pharmaceuticals has charted a significant course since its founding, marked by strategic growth and pivotal drug development milestones. The company's journey from a startup to a publicly traded entity underscores its commitment to addressing unmet medical needs.

Pipeline Expansion in Nephrology

Apellis is set to launch EMPAVELI for C3G and primary IC-MPGN in the latter half of 2025. The company is also initiating two Phase 3 trials for EMPAVELI in FSGS and DGF during the same period.

Market Confidence and Financial Outlook

Analysts project an average stock price target of $33.88 by August 2026, suggesting a potential upside of 39.03%. The company anticipates its cash reserves and product revenues will fund operations to profitability.

Strategic Focus and Vision Alignment

The company's forward-looking strategy is grounded in its founding vision of leveraging complement science. This approach aims to continue delivering impactful therapies for patients with severe and rare diseases.

Continued Drug Development and Approvals

Apellis's history includes significant achievements like the FDA approval of Empaveli and Syfovre. The recent approval of EMPAVELI for C3G and primary IC-MPGN further expands its therapeutic reach in rare kidney diseases.

Apellis Pharmaceuticals Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔